Chinemerem M Emeasoba
Researcher
Also affiliated: Imo State University (2023); Fayetteville VA Medical Center (2025); Washington Regional Medical Center (2025); Fayetteville Public Library (2026); Northwest Medical Specialties (2026)
Faculty Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Chinemerem M Emeasoba's research focuses on population-based health outcomes, particularly within the context of cancer and cardiovascular disease. Emeasoba has investigated the survivability of immunotherapy for colon cancer and analyzed the incidence of myocardial infarction, deep venous thrombosis, and pulmonary embolism in patients hospitalized with SARS-CoV-2. Further work examines histology-dependent survival and treatment benefits in primary tracheal cancer, as well as demographic and socioeconomic disparities in colorectal cancer screening utilization and stage at diagnosis. Emeasoba has also explored comparative outcomes of different generations of tyrosine kinase inhibitors for chronic myeloid leukemia and the prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors. Recent studies also involve demographic and socioeconomic disparities in access to surgery for thymic carcinoma and the development of machine learning models to predict mortality in salivary gland cancer.
Metrics
- h-index: 1
- Publications: 25
- Citations: 7
Selected Publications
-
Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study (2026)
-
Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis. (2026)
-
Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021. (2026)
-
Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis. (2026)
-
Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis. (2026)
-
HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap (2026)
-
HSR26-266: Navigating the Burden of Cure: Defining Survivorship Pathways in Head and Neck Cancer (2026)
-
BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer (2026)
-
Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises (2026)
-
Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer. (2026)
-
Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients. (2026)
-
495 Breaking the recurrence barrier in colon cancer: ATOMIC trial doubles disease-free survival with atezolizumab+mFOLFOX6 (2025)
-
1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles (2025)
-
776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms (2025)
-
426 Reprogramming tumor metabolism to overcome immune evasion: GLUT1 blockade synergizes with PD1/CTLA-4 therapy in non-small cell lung cancer (2025)
Collaboration Network
Top Collaborators
- 426 Reprogramming tumor metabolism to overcome immune evasion: GLUT1 blockade synergizes with PD1/CTLA-4 therapy in non-small cell lung cancer
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
- 495 Breaking the recurrence barrier in colon cancer: ATOMIC trial doubles disease-free survival with atezolizumab+mFOLFOX6
- Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients.
Showing 5 of 12 shared publications
- 426 Reprogramming tumor metabolism to overcome immune evasion: GLUT1 blockade synergizes with PD1/CTLA-4 therapy in non-small cell lung cancer
- 495 Breaking the recurrence barrier in colon cancer: ATOMIC trial doubles disease-free survival with atezolizumab+mFOLFOX6
- Differential neurotoxicity patterns across neuroendocrine tumor grades: A real-world analysis of 12,847 patients.
- Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis.
- Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021.
Showing 5 of 6 shared publications
- Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer.
- BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer
- HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap
- Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis.
- Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021.
- Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state.
- HSR26-266: Navigating the Burden of Cure: Defining Survivorship Pathways in Head and Neck Cancer
- Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis.
- Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis.
- Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises
- Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer.
- BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer
- HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap
- Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
- Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises
- Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
- Liver Cirrhosis and In‐Hospital Outcomes in Patients With Sickle Cell Crises
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
- BPI26-006: Too Late to Test: Real-World Impact of MSI/MMR Testing Delays on Survival and Treatment in Colorectal Cancer
- HSR26-267: Evidence-Based Radiotherapy in Early Breast Cancer: Closing the Hypofractionation Gap
- Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis.
- Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis.
- Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis.
- Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis.
- Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021.
- Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis.
- Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
Similar Researchers
Based on overlapping research topics